[
    [
        {
            "time": "",
            "original_text": "H P V 疫苗国产背后的生意经：“一针难求”待解 有公司毛利90％",
            "features": {
                "keywords": [
                    "HPV疫苗",
                    "国产",
                    "生意经",
                    "一针难求",
                    "高毛利"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药周报：关注细分领域里质地优良、估值相对合理具有安全边际、增长确定性强的标的",
            "features": {
                "keywords": [
                    "医药",
                    "周报",
                    "细分领域",
                    "质地优良",
                    "估值合理",
                    "安全边际",
                    "增长确定性"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中国银河 - 万泰生物：IVD+疫苗双轮驱动，业绩高速增长【公司研究】",
            "features": {
                "keywords": [
                    "中国银河",
                    "万泰生物",
                    "IVD",
                    "疫苗",
                    "双轮驱动",
                    "业绩高速增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国银河 - 万泰生物：IVD+疫苗双轮驱动，业绩高速增长【公司研究】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]